MycoLogics, Inc. Press Releases - PRWeb Press Release Group http://www.rsspad.com/rss2/10165.xml MycoLogics, Inc. Press Releases - Powered by PRWeb and RSSPad en xml@emediawire.com xml@emediawire.com 30 MycoLogics, Inc. San Joaquin Valley Fever Vaccine Demonstrates Proof-of-Concept in Animal Model http://www.prweb.com/releases/2006/09/prweb439910.htm MycoLogics, Inc., today announced that its prophylactic vaccine against coccidioidomycosis, also known as San Joaquin Valley Fever (SJVF), demonstrated statistically significant proof-of-concept results in an animal model assay. (PRWeb Sep 21, 2006)

Read the full story at http://www.prweb.com/releases/2006/09/prweb439910.htm

]]> Thu, 21 Sep 2006 07:00:00 GMThttp://www.prweb.com/releases/2006/09/prweb439910.htm MycoLogics, Inc. to Present Results at 46th Annual International Conference on Antimicrobial Agents and Chemotherapy Conference http://www.prweb.com/releases/2006/07/prweb409655.htm Will present animal model data showing the efficacy of MycoLogics proprietary prophylactic vaccine against aspergillosis. (PRWeb Jul 12, 2006)

Read the full story at http://www.prweb.com/releases/2006/07/prweb409655.htm

]]> Wed, 12 Jul 2006 07:00:00 GMThttp://www.prweb.com/releases/2006/07/prweb409655.htm MycoLogics, Inc. Further Expands Antifungal Intellectual Property Portfolio http://www.prweb.com/releases/2004/10/prweb172500.htm MycoLogics, Inc., an innovative biotechnology company specializing in the development of novel antifungal drugs and therapeutic and prophylactic vaccines, today announced the receipt of patent 6,730,495 and 6,743,598, awarded by the U.S. Patent and Trademark Office, for the discovery of compositions and methods related to both the identification of antimicrobial compounds and for the identification of fungal glucose utilization inhibitors and antifungal agents. (PRWeb Oct 29, 2004)

Read the full story at http://www.prweb.com/releases/2004/10/prweb172500.htm

]]> Fri, 29 Oct 2004 07:00:00 GMThttp://www.prweb.com/releases/2004/10/prweb172500.htm MycoLogics, Inc. Expands MycoDetect™ Suite of Antifungal Compound Identification Screening Services http://www.prweb.com/releases/2004/09/prweb158820.htm MycoLogics, Inc., today announced the availability of MycoDetect™, a comprehensive screening service used to identify active antifungal compounds. (PRWeb Sep 17, 2004)

Read the full story at http://www.prweb.com/releases/2004/09/prweb158820.htm

]]> Fri, 17 Sep 2004 07:00:00 GMThttp://www.prweb.com/releases/2004/09/prweb158820.htm MycoLogics, Inc. To Identify Novel Drug for Treatment of Leishmaniasis (Baghdad Boil) http://www.prweb.com/releases/2004/08/prweb150875.htm MycoLogics, Inc., an innovative biotechnology company specializing in the development of novel drugs and vaccines for the prevention and treatment of infectious diseases, today announced the award of a Phase I SBIR grant by the National Institutes of Health to identify a lead drug compound for human clinical trials for the treatment of leishmaniasis. (PRWeb Aug 20, 2004)

Read the full story at http://www.prweb.com/releases/2004/08/prweb150875.htm

]]> Fri, 20 Aug 2004 07:00:00 GMThttp://www.prweb.com/releases/2004/08/prweb150875.htm MycoLogics, Inc. Continues to Expand Antifungal Intellectual Property Portfolio http://www.prweb.com/releases/2004/06/prweb136727.htm MycoLogics, Inc., an innovative biotechnology company specializing in the development of novel antifungal drugs and therapeutic and prophylactic vaccines, today announced the receipt of patent 6,716,625, awarded by the U.S. Patent and Trademark Office, for the discovery of compositions and methods related to fungal histidine kinases and their use in screening compounds for antifungal activity, in addition to the development of antifungal compounds. (PRWeb Jun 26, 2004)

Read the full story at http://www.prweb.com/releases/2004/06/prweb136727.htm

]]> Sat, 26 Jun 2004 07:00:00 GMThttp://www.prweb.com/releases/2004/06/prweb136727.htm MycoLogics, Inc. to Develop a High Throughput Screen Used to Identify Antifungal Drugs http://www.prweb.com/releases/2004/04/prweb116191.htm MycoLogics, Inc. today announced award of a Phase I SBIR grant by the Department of Health and Human Services to isolate a new class of compounds by disrupting beta(1,3)-glucan synthesis using a novel assay. (PRWeb Apr 3, 2004)

Read the full story at http://www.prweb.com/releases/2004/04/prweb116191.htm

]]> Sat, 03 Apr 2004 08:00:00 GMThttp://www.prweb.com/releases/2004/04/prweb116191.htm